Develops 3D bioprinting technology for tissue engineering and drug discovery applications.
Organovo Holdings, Inc., headquartered in Solana Beach, California, is a pioneering biotechnology company focused on advancing the field of regenerative medicine through its innovative 3D tissue technology. Established in 2007, Organovo specializes in developing bioprinted tissues that closely mimic key aspects of human physiology and disease.
At the heart of Organovo's capabilities is its proprietary NovoGen Bioprinting platform, featuring advanced automated devices that facilitate the creation of 3D living tissues using mammalian cells. These technologies include specialized bio-inks and methods for bioprinting multicellular tissues with intricate architectures, offering researchers and pharmaceutical companies unpreccedented tools for predictive preclinical testing.
Organovo is renowned for its ExVive human liver tissue and ExVive human kidney tissue products, which are utilized extensively in drug discovery and development. These tissue models provide accurate physiological insights that aid in assessing drug efficacy, toxicity, and metabolism, thereby streamlining the drug development process and reducing reliance on animal testing. With a commitment to innovation and scientific excellence, Organovo continues to drive forward the possibilities of regenerative medicine and tissue engineering, paving the way for transformative advancements in healthcare.